A patient eight months into weekly injections asks whether she can move to tablets and keep her results. Another rings having read that a pill is now licensed, and wants to start on it instead of injecting at all. Both conversations have been landing in aesthetic clinics since 11 June 2026, when the MHRA licensed oral semaglutide for weight management. The Wegovy pill runs on a four-strength titration, and the two that open it are Wegovy 1.5mg tablets and Wegovy 4mg tablets, each supplied in packs of 30 that cover a month exactly. Same molecule practitioners already know, in a form that behaves quite differently in daily use. The clinical questions it raises are not the ones the injection raised.
How the Wegovy Weight Loss Pill Works?
Semaglutide is a GLP-1 receptor agonist. It binds GLP-1 receptors in the hypothalamus to increase satiety and reduce appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. None of that is new. What is new is getting a peptide of that size across the gastric mucosa intact.
Peptides are destroyed by gastric acid and enzymes, which is why GLP-1 therapies started as injections. The tablet solves this with SNAC, an absorption enhancer co-formulated alongside the semaglutide. SNAC raises pH locally around the tablet as it dissolves, protecting the semaglutide from degradation and promoting absorption across the stomach wall. The effect is localised and short-lived, which is why the tablet must be taken whole and alone.
Oral bioavailability remains low and variable between individuals. That variability is the single most important thing to understand about the product, because almost all of it is controlled by how the patient takes it.
Why the fasting window is not optional
The Wegovy 25 mg tablets Summary of Product Characteristics is specific. The tablet is taken after a fast of at least eight hours, swallowed whole with up to 120 mL of water, and nothing else — no food, no other drink, no other oral medicines — for at least 30 minutes afterwards. Tablets must not be split, crushed or chewed.
In practice this catches out patients who take a morning levothyroxine, a PPI, or a combined oral contraceptive. All of those move to after the 30-minute window. Black coffee counts as a drink. Taking the tablet with a full glass of water rather than a sip dilutes the SNAC and reduces absorption. A patient who reports no effect at all is often a patient who has been taking it with breakfast.
Wegovy Pill Doses and the Four-Step Titration
Treatment runs through four strengths: 1.5 mg, 4 mg, 9 mg and 25 mg once daily, with a minimum of one month at each level before stepping up. The strengths escalate on 30-day blocks rather than four-week blocks, and each pack contains 30 tablets, so one pack equals one step exactly.
That distinction matters more than it sounds. A clinic running reviews on a four-week cycle will be six days ahead of the label by the time the patient reaches 25 mg. Over a titration that is a week of supply out of alignment, and it puts the highest dose in the patient’s hands earlier than the licence intends. Book the reviews on dates, not on weeks.
Escalation can be delayed if a dose is not tolerated. Holding a patient at 4 mg for a second month is a legitimate clinical decision, not a failure of the protocol.
Patients already established privately on the 2.4 mg weekly injection can move directly to 25 mg tablets daily without re-titrating.
Wegovy 1.5mg Tablets: The First 30 Days
Wegovy 1.5mg tablets come as a pack of 30, covering the opening month exactly. This is a tolerance-building dose. It is not expected to produce weight loss, and telling patients otherwise at consultation is the fastest route to a month-two dropout.
Set the expectation plainly: the first two months are about getting the gut used to the drug. Some appetite change may be noticeable. Meaningful loss is not the target yet.
Wegovy 4mg Tablets: Days 31 to 60
Wegovy 4mg tablets are the second titration step, again 30 tablets to 30 days. Appetite suppression becomes more apparent for some patients here, though clinically significant weight reduction generally begins from 9 mg upward.
The common error at this stage is stepping up early because the patient reports nothing is happening. Compressing the titration reliably increases nausea and vomiting, and a patient who is vomiting is a patient who stops treatment.
Wegovy Pill vs Injection: What Changes in Practice
OASIS 4 randomised 307 adults with obesity, or overweight with a comorbidity, to once-daily oral semaglutide or placebo across 64 weeks. Mean weight loss came out at 13.6%, and closer to 16.6% among participants who stayed on treatment throughout. Those are the figures the MHRA worked from, and they sit close to what the 2.4 mg injection achieves. On efficacy grounds, the choice between tablet and pen is not the deciding factor.
Two things temper that for a UK caseload. The trial ran against placebo with no active comparator, so “as effective as the injection” is a cross-trial inference rather than a head-to-head result, and it says nothing at all about tirzepatide, which is what most privately treated patients in the UK are actually on. The cohort was also 92% White and 79% female. Practitioners treating South Asian, Black African and African-Caribbean patients, where metabolic risk presents at lower BMI, are extrapolating from a population the trial recruited very little of. Worth reading the published OASIS 4 results before quoting the headline percentage at a consultation.
Three notes on the swap. The tirzepatide line sets up the how Mounjaro, Wegovy and Ozempic compare link in the paragraph below it, so that internal link now earns its place instead of sitting there loosely. The generalisability point is a real gap in the UK content on this drug — nobody else covering the Wegovy pill is raising it, and it’s the kind of thing that gets a post cited. And the post now has no corporate press release in it at all, which fits the sourcing line you drew on the finance piece.
Wegovy Pill Side Effects and What Patients Report
Gastrointestinal effects dominate, as with every GLP-1. In OASIS 4, nausea affected around 46.6% of participants on oral semaglutide against 18.6% on placebo, concentrated around initiation and each dose increase. Serious adverse events were actually less frequent on the drug than on placebo, at 3.9% against 8.8%.
The effects practitioners need to counsel on beyond nausea come from the UK SmPC. Acute pancreatitis has been reported with GLP-1 receptor agonists: patients should know the symptoms, semaglutide should be stopped if it is suspected, and it should not be restarted if confirmed. There is an epidemiological signal for non-arteritic anterior ischaemic optic neuropathy. Patients with type 2 diabetes and existing retinopathy need monitoring. Anyone on insulin or a sulfonylurea carries an increased hypoglycaemia risk and may need those doses reduced. Semaglutide is not recommended in severe hepatic impairment, and must never be combined with another GLP-1 receptor agonist.
The only absolute contraindication in the UK label is hypersensitivity to semaglutide or the excipients. Practitioners who have absorbed US-sourced guidance sometimes quote the medullary thyroid carcinoma warning as a contraindication. That sits in the American labelling, not the UK SmPC, though it remains a reasonable thing to explore in history-taking.
One easily missed point: pulmonary aspiration has been reported in patients on GLP-1 agonists undergoing general anaesthesia or deep sedation. Any patient heading for surgery needs their anaesthetist told they are on it.
Published Wegovy pill reviews from patients are still thin and heavily weighted toward the first month, when GI symptoms peak and results have not arrived. They are a poor guide to what the drug does over a year. The practitioner field guide to Mounjaro side effects covers the same escalation-and-management logic that applies here. Suspected reactions should go to the MHRA Yellow Card scheme.
Wegovy Pill UK Availability and NHS Access
The MHRA approval of the semaglutide tablet made the UK the first country in Europe to license an oral GLP-1 for weight management. Access since then has been private prescription only.
NICE has not appraised the tablet. TA875 covers injectable semaglutide through specialist weight management services, and that recommendation does not extend to the oral form. A separate or updated appraisal would be needed, and appraisals typically run 6–18 months from licensing. No NHS route is expected during 2026, which means private clinics are the access point for the foreseeable future.
Wegovy Pill Cost and What Clinics Should Plan For
Novo Nordisk has not published a UK list price, and pharmacy pricing varies considerably by strength and supplier. Any single Wegovy pill price quoted online should be read as one pharmacy’s position on one strength at one moment, not a market rate. Private prescriptions also attract 20% VAT, which is often absent from headline figures.
The structural point for clinics is that cost rises with dose. The two titration strengths are the cheapest months of the course, and the 25 mg maintenance strength is both the most expensive and the one patients remain on indefinitely. A Wegovy pill UK price modelled on month one will understate the twelve-month picture substantially. Build the patient conversation around annual cost, and be direct that stopping generally means regaining.
Trade pricing on Faces sits behind login and requires an active prescriber connection, so the figures a clinic sees are the ones that actually apply to that clinic.
Where to Buy Wegovy Pill Stock Legally in the UK
Wegovy pill UK supply runs the same route as every other GLP-1 in the marketplace: prescription first, pharmacy second. A prescription must come from an appropriate practitioner following an adequate assessment, and dispensing must go through a GPhC-registered pharmacy. Non-prescribing practitioners cannot hold stock against future patients.
Clinics looking to buy Wegovy tablets for clinic stock on Faces need to connect with a prescriber before pricing becomes visible, which trips up practitioners who expect to browse and buy in one step. The sequence is prescriber connection, then pricing, then order. The same logic set out in how to buy Mounjaro online for your clinic applies directly.
Two adjacent points. A Wegovy consent form should be updated to reflect oral administration, because the fasting requirements and interaction window are not covered by injection consent wording. And the rules on advertising Botox in the UK apply identically here, since prescription-only medicines cannot be advertised to the public whatever the drug class.
Order Wegovy 1.5mg Tablets and Wegovy 4mg Tablets on Faces
Stocking the tablet starts with a prescriber, not a basket. Find a prescriber near you on Faces, connect, and live pricing on Wegovy 1.5mg tablets and Wegovy 4mg tablets unlocks for your clinic, with next day delivery on in-stock lines.
FAQs
How much is the Wegovy pill?
There is no single figure. The Wegovy pill price UK market currently varies by dose strength and supplier, with the lowest costs at the 1.5 mg starting dose and the highest at 25 mg maintenance. Novo Nordisk has not published a UK list price, so any figure quoted is a specific pharmacy’s pricing rather than a national rate.
When will the Wegovy pill be available?
It already is. The tablet launched in the US in January 2026 following FDA approval the previous December, and became available privately in the UK from July 2026.
How much will the Wegovy pill cost in the UK?
Over a full year, Wegovy pill cost UK totals depend mostly on how quickly a patient reaches 25 mg and stays there, since maintenance is the dominant expense. Clinics should also factor in consultation and review appointments, which are usually priced separately from the medicine.
Where can UK clinics buy the Wegovy pill?
Through a GPhC-registered pharmacy, against a valid prescription. Practitioners searching Wegovy pill UK where to buy should be aware that any supplier willing to sell without a prescription is operating illegally, and stock from those routes cannot be verified.